SerbiaThe article discusses the case of Ognjen Bojković, a 13-year-old boy suffering from epidermolysis bullosa, a rare genetic skin disorder often referred to as 'butterfly children's disease.' The condition causes severe skin fragility, leading to open wounds, infections, and mobility challenges. A new treatment called 'Vyuvek' developed by American company Krystal Biotech has shown promise in preventing infections, closing wounds, improving immunity, and extending life expectancy for patients with this condition. However, the treatment is expensive, and Ognjen’s family is seeking financial help.
Bias read (Center): The article presents a factual account of a medical condition, the associated treatment, and the family's need for financial assistance. There is no evident ideological framing, biased language, or selective sourcing. The focus is on the health challenge and the practical need for funding, without a
Why these scores (Factual 40 · Objective 70): The article mentions Epidermolysis Bullosa but incorrectly links it to PHOX2B mutations and Congenital Central Hypoventilation Syndrome (CCHS). There is no evidence in the primary sources connecting these conditions. The claim about 'Vuvek' drug is not supported by any cited research. The factual ac
